Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada-Reference-Cited by-同舟云学术

Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada

Published:2021-06-25 Issue:6 Volume:4 Page:e2114531
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Lythgoe Mark P.¹,Middleton Paul²

Affiliation:

1. Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, United Kingdom

2. Department of Metabolism, Digestion and Reproduction, Imperial College London, St Mary’s Hospital, United Kingdom

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2781352/lythgoe_2021_ld_210114_1623785654.16558.pdf

Reference6 articles.

1. Regulatory decision-making on COVID-19 vaccines during a public health emergency.;Avorn;JAMA,2020

2. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012.;Downing;JAMA,2014

3. Speed, evidence, and safety characteristics of vaccine approvals by the US Food and Drug Administration.;Puthumana;JAMA Intern Med,2021

4. US Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19. June 2020. Accessed March 17, 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19

5. Government of Canada. Vaccines and treatments for COVID-19: progress. Accessed April 21, 2021. https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks/covid-19-vaccine-treatment.html#a2

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of interim oncology treatments introduced for solid cancers during the COVID-19 pandemic in England: a retrospective evidence-based analysis;The Lancet Regional Health - Europe;2024-11

2. Nanoparticle-Mediated Mucosal Vaccination: Harnessing Nucleic Acids for Immune Enhancement;Current Microbiology;2024-07-20

3. Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges;npj Vaccines;2024-05-23

4. Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data;Vaccine;2024-03

5. The experiences of community health workers when communicating with refugees about COVID-19 vaccines in Syracuse, NY: A qualitative study;Heliyon;2024-02